Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

Depreciation & Amortization · Q4 FY2024 · quarter ended Dec 2024

Depreciation & amortization outflow shrinks to $0

Q4 FY2024 depreciation & amortization was $0, compared with $3.54K a year earlier.

Context

  • Depreciation & amortization amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2024
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Depreciation & Amortization vs competitors

How NNNN compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Depreciation & amortization amounts to 0.0% of revenue for NNNN, versus a peer median of 2.0%.
NNNN Competitors
Depreciation & Amortization for NNNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYHCommunity Health Systems, Inc.LTM Mar 2026$435M USD-8.6%-7.3%2.0%
SNDLSNDL Inc.LTM Mar 2026CA$56.2M CAD-0.2%+5.9%6.0%
AVNSAvanos Medical, Inc.LTM Mar 2026$39.5M USD-9.6%-6.6%5.5%
ANGOAngioDynamics, Inc.LTM Feb 2026$23.19M USD-13.4%-4.2%7.4%
TALKTalkspace, Inc.LTM Mar 2026$3.46M USD+164.5%+28.4%1.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$2.41M USD-1.0%+34.3%0.8%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$1.76M USD+64.4%+8.1%4.3%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$1.19M USD——1.0%
GOSSGossamer Bio, Inc.LTM Mar 2026$892K USD-74.4%-39.1%1.6%
CMPSCOMPASS Pathways plcLTM Mar 2026$179K USD-14.4%-13.2%—
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$0 USD——0.0%
Peer median (excluding NNNN) —-8.6%-4.2%2.0%

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income2.54M10.01M2.25M2.37M6.4M
Depreciation & Amortization06.25K12.06K00
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.65M(5.53M)(1.2M)44.65K(13.21M)
Accounts Receivables(717.5K)717.5K(1.88M)820.17K(2.59M)
Inventory0(353.87K)353.87K00
Accounts Payables1.89M(481.82K)(580.89K)798.1K(1.63M)
Other Working Capital473.15K(5.41M)907.97K(1.57M)(8.99M)
Other Non-Cash Items1(40.87K)(163.39K)(337.1K)68K
Operating Cash Flow4.18M4.45M898.37K2.08M(6.74M)
Capital Expenditures0(3)000
Acquisitions (Net)00000
Purchases of Investments0(16.09M)(18.54M)(35.47M)(19.42M)
Sales of Investments014.56M20.27M35.8M15.22M
Other Investing Activities00000
Investing Cash Flow0(1.53M)1.73M337.1K(4.2M)
Debt Repayment00000
Common Stock Issued00007.23M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00(42.84K)(344.61K)(282.55K)
Financing Cash Flow00(42.84K)(344.61K)6.95M
Effect of Forex Changes00000
Net Change in Cash4.18M2.92M2.59M2.07M(3.99M)
Free Cash Flow4.18M4.45M898.37K2.08M(6.74M)

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.